CLAIMS

1) An ophthalmic composition comprising hyaluronic acid and arabinogalactan in synergistic amounts for use in the treatment of dry-eye syndrome.

2) An ophthalmic composition comprising hyaluronic acid and arabinogalactan in synergistic amounts according to claim 1, for use in the treatment of dry-eye syndrome, accompanied by the inflammatory phenomena related to the action of the enzyme system xanthine dehydrogenase/xanthine oxidase, which are reduced due to the combined and synergistic action of the two active ingredients hyaluronic acid and arabinogalactan.

3) An ophthalmic composition according to claim 1 or 2, further comprising panthenol, trehalose and vitamin E-D-α-polyethylene glycol (TGPS), for use in the treatment of dry-eye syndrome, accompanied by the inflammatory phenomena related to the action of the enzyme system xanthine dehydrogenase/xanthine oxidase.

4) The ophthalmic composition for use according to any one of claims 1 to 3, characterized in that the hyaluronic acid amount ranges from 0.15% to 0.4% by weight, on the total weight.

5) The ophthalmic composition for use according to any one of claims 1 to 3, characterized in that the arabinogalactan amount ranges from 0.40% to 1.00% by weight, on the total weight.

6) The ophthalmic composition for use according to claim 3, characterized in that the panthenol amount ranges from 0.30% to 0.60% by weight, on the total weight.

7) The ophthalmic composition for use according to claim 3, characterized in that the trehalose amount ranges from 3.00% to 4.00% by weight, on the total weight.

8) The ophthalmic composition for use according to claim 3, characterized in that the vitamin E-D-α-polyethylene glycol (TGPS) amount is comprised between 0.030% to 0.050% by weight, on the total weight.

9) The ophthalmic composition for use according to claim 3, characterized in that it is filterable and sterilizable at 0.2 microns.

10) The ophthalmic composition for use according to claim 1 or 3, further comprising one or more additional therapeutic agents, selected from the group comprising growth factors, anti-inflammatory agents, vitamins, fibronectin and collagen, amino acids and/or pharmacologically acceptable substances for the treatment of dry-eye syndrome, accompanied by the inflammatory phenomena related to the action of the enzyme system xanthine dehydrogenase/xanthine oxidase.

11) The ophthalmic composition for use according to claim 3, further comprising a gelling agent such as Poloxamer 407, in a range of concentrations between 1% and 9% by weight.

12) A method of preparing an eye drop comprising both hyaluronic acid and arabinogalactan, suitable for the treatment of dry-eye syndrome, in synergistic amounts, for preparing, after sterilization by filtration, an ophthalmic product for topical use in the form of eye drops for the treatment of dry-eye syndrome.

13) Use of a composition comprising a hyaluronic acid and arabinogalactan association, further comprising panthenol, trehalose, and vitamin E-D-α-polyethylene glycol (TGPS), for producing eye drops for the treatment of dry-eye syndrome, after sterilization by filtration.

14) Use of a composition comprising a hyaluronic acid and arabinogalactan association, further comprising panthenol, trehalose, and vitamin E-D-α-polyethylene glycol (TGPS), with the addition of a gelling agent, such as Poloxamer 407, for producing a gel for the treatment of dry-eye syndrome.

15) Use of a composition comprising hyaluronic acid, arabinogalactan, panthenol, trehalose and vitamin E-D-α-polyethylene glycol (TGPS), for preparing eye drops or a gel for the treatment of dry-eye syndrome, accompanied by the inflammatory phenomena related to the action of the enzyme system xanthine dehydrogenase/xanthine oxidase.